BACKGROUND
Automated insulin delivery (AID) systems are recommended for individuals with diabetes requiring insulin. Real-world effectiveness may differ from outcomes reported in prospective clinical trials. The twiist™ AID system recently received regulatory clearance, and real-world glycemic outcomes have not been pr...
Viral N. Shah, Peter J. Jacobs, Grazia Aleppo et al.· Diabetes Technology & Therap...· 0 citations
OBJECTIVE The value of adding continuous glucose monitoring (CGM) to blood glucose monitoring (BGM) during pregnancy is unclear. PURPOSE To clarify CGM's role in pregnancy using meta-analysis, Grading of Recommendations Assessment, Development and Evaluation (GRADE) ratings, harmonized neonate size definitions, and tri...
R. Bannuru, M. Noble, Grazia Aleppo et al.· Diabetes, obesity, and cardi...· 0 citations
INTRODUCTION
Basal insulin dose titration has historically relied on fasting self-monitoring blood glucose (SMBG) and hypoglycemic events. This retrospective analysis of the QWINT-2 and QWINT-3 Phase 3 trials aimed to evaluate the use of continuous glucose monitoring (CGM)-derived indicators for weekly insulin efsitora...
R. Bergenstal, Michael B. Davidson, David T. Ahn et al.· Diabetes Technology & Therap...· 0 citations
Randomized and real-world studies demonstrate that AID systems significantly improve A1C and time in range while minimizing hypoglycemia, without increasing treatment complexity or patient burden, and position AID as a practical and effective strategy to overcome long-standing therapeutic inertia in type 2 diabetes.
Z. Tariq, Grazia Aleppo, Anders L. Carlson et al.· Endocrine Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.